Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lactobacillus reuteri CCFM1132 for relieving hyperuricemia and ulcerative colitis and application

A technology of CCFM1132 and Lactobacillus reuteri, applied in the field of microorganisms, can solve problems such as unclear pathogenesis, many side effects, and limited efficacy of therapeutic drugs, so as to relieve hyperuricemia and gout, improve disease symptoms, and reduce hyperuricemia The effect of blood and gout

Active Publication Date: 2022-03-18
JIANGNAN UNIV
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the pathogenesis of inflammatory bowel disease is still unclear, and the therapeutic effects of the drugs used are relatively limited and have many side effects. The use of preventive or adjuvant therapy for IBD has great potential

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lactobacillus reuteri CCFM1132 for relieving hyperuricemia and ulcerative colitis and application
  • Lactobacillus reuteri CCFM1132 for relieving hyperuricemia and ulcerative colitis and application
  • Lactobacillus reuteri CCFM1132 for relieving hyperuricemia and ulcerative colitis and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Example 1: Screening of Lactobacillus reuteri CCFM1132

[0052] (1) Isolation and screening of Lactobacillus

[0053] (1) Take 1g of fresh feces of healthy adults. After gradient dilution, it was applied to LBS medium supplemented with 1% nystatin, and placed in a constant temperature incubator at 37°C for 48 hours.

[0054] (2) After cultivation, according to the color, size, and edge shape of the colony, use an inoculation loop to pick up the colony and streak it for purification.

[0055] (3) The obtained colonies were subjected to Gram staining and catalase analysis.

[0056] (4) Retain Gram-positive bacilli and catalase-negative bacteria.

[0057] (2) Molecular biological identification of Lactobacillus

[0058] (1) Single bacterial genome extraction

[0059] (A) cultivating the lactobacilli screened in step (1) overnight;

[0060] (B) Take 1 mL of the bacterial suspension cultivated overnight in a 1.5 mL centrifuge tube, centrifuge at 10000 r / min for 2 min, ...

Embodiment 2

[0076] Example 2: Lactobacillus reuteri CCFM1132 has no toxic side effects on KunMing mice

[0077] Lactobacillus reuteri CCFM1132 was cultured in MRS medium at 37°C, the bacteria were collected, and the bacteria were resuspended in 100g / L skim milk solution to make a concentration of 4.0×10 9 CFU / mL bacterial suspension. Take 12 healthy male KunMing mice with a body weight of about 24-32g. After adapting to the environment for a week, they are divided into CCFM1132 group and control group. The 100g / L skim milk solution that does not contain Lactobacillus reuteri CCFM1132 was observed for a week, and the death and body weight were recorded.

[0078] The results of these tests are listed in Table 1. These results indicate that feeding concentrations of 1×10 9 CFU / Lactobacillus reuteri CCFM1132 had no significant impact on mice, no significant change in body weight, and no death. The appearance of the mice had no obvious pathological symptoms.

[0079] Table 1 Changes in bo...

Embodiment 3

[0082] Example 3: Lactobacillus reuteri CCFM1132 reduces serum uric acid levels in hyperuricemia mice

[0083] Twenty-four healthy male KunMing mice with a body weight of 24-32 g were taken, and after one week of adaptive culture, they were randomly divided into 4 groups, namely the control group, hyperuricemia model group, Lactobacillus reuteri CCFM1132 intervention group and allopurin Alcohol intervention group (allopurinol). Except for the control group, 500mg / kg BW hypoxanthine was intragastrically administered to other groups every day, and 200mg / kg BW oxonate potassium was intraperitoneally injected 1 hour later; 1 hour before oxonate potassium treatment, the control group and the hyperuricemia model group were given 100g / L skimmed milk, Lactobacillus reuteri CCFM1132 intervention group was given 1.0×10 9 CFU / Lactobacillus reuteri CCFM1132, the allopurinol group was given 5mg / kgBW allopurinol. The experimental groups and processing methods are shown in Table 2:

[008...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses lactobacillus reuteri CCFM1132 capable of relieving hyperuricemia and ulcerative colitis and application of the lactobacillus reuteri CCFM1132, and belongs to the technical field of microorganisms. The lactobacillus reuteri CCFM1132 can reduce the serum uric acid level of a mouse with hyperuricemia, inhibit the activity of xanthine oxidase (XOD) of serum and liver, and reduce the occurrence of hyperuricemia and gout; the serum creatinine level can be lowered, the serum total triglyceride (TG) can be lowered, and the activity of serum alkaline phosphatase (ALP) can be inhibited; and the expression of ileum uric acid transporter ABCG2 is promoted. The lactobacillus reuteri CCFM1132 disclosed by the invention can improve the disease activity index of a patient with colitis, can be used for preparing functional microbial agents, foods and medicines for relieving hyperuricemia, gout and inflammatory bowel diseases, and has a wide application prospect.

Description

technical field [0001] The invention relates to Lactobacillus reuteri CCFM1132 for relieving hyperuricemia and ulcerative colitis and its application, belonging to the technical field of microorganisms. Background technique [0002] Hyperuricemia (Hyperuricemia, HUA) refers to a disease in which the level of uric acid in the blood exceeds the normal value. In recent years, with the improvement of living standards, the incidence of hyperuricemia is also increasing. In my country, patients with hyperuricemia account for about 13.3% of the total population. Urate stones caused by long-term hyperuricemia can further induce gout. At the same time, hyperuricemia is considered a risk factor for cardiovascular and cerebrovascular diseases, chronic kidney disease, and atherosclerosis, which seriously endangers human health. Therefore, the treatment of hyperuricemia has attracted great attention. At present, the drugs for the treatment of hyperuricemia mainly include allopurinol (xa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N1/20A61K35/747A61P19/06A61P1/04A23L33/135A23L29/00C12R1/225
CPCC12N1/20A61K35/747A61P19/06A61P1/04A23L33/135A23L29/065A23V2002/00A23V2400/173A23V2200/30A23V2200/3204Y02A50/30C12N1/205C12R2001/225
Inventor 王刚倪彩新郑雨星王琳琳赵建新张灏陈卫
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com